Hormonal
Elevated tissue levels of specific ceramide species (C16:0 and C18:0) directly cause insulin resistance and metabolic dysfunction by inhibiting Akt/PKB signaling and mitochondrial efficiency.
High levels of specific fats called ceramides (C16:0 and C18:0) block your body's ability to use insulin, leading to high blood sugar and metabolic disease. While not all fats are bad, these specific ones are key drivers of insulin resistance. Managing overall metabolic health involves addressing these specific lipid accumulations, often through lifestyle changes that improve insulin sensitivity.
sphingolipids such as ceramides are particularly impactful, as they elicit the selective insulin resistance, dyslipidemia, and ultimately cell death that underlie nearly all metabolic disorders.
Why this rating
Strong evidence from multiple rodent models, genetic manipulations, and large human cohort studies correlating ceramide levels with disease.
Source
Ceramides in Metabolism: Key Lipotoxic Players
Bhagirath Chaurasia et al. · Annual Review of Physiology · 2020
DOI 10.1146/annurev-physiol-031620-093815
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →